Physician profile
Violet Kramer
NPI 1033314745
$2,154.83
in general payments reported to CMS, 2019-2025
24 companies · $599 in 2025
The $599 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $243 · 2021: $209 · 2022: $233 · 2023: $223 · 2024: $366 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.59 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $393.63 | 2019-2025 | Fasenra, Andexxa, Breztri |
| Actelion Pharmaceuticals US, INC. | $310.63 | 2019-2024 | Uptravi |
| Mallinckrodt Hospital Products INC. | $150.00 | 2024 | Terlivaz |
| Glaxosmithkline, LLC. | $147.32 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.43 | 2019-2025 | Ofev |
| Viatris Specialty LLC | $133.97 | 2025 | Yupelri |
| Portola Pharmaceuticals, LLC | $119.05 | 2020 | |
| Shionogi INC | $118.60 | 2025 | Fetroja |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Pulmonx Corporation | $92.28 | 2022 | |
| Mylan Specialty L.P. | $66.78 | 2019-2024 | Yupelri |
| Harmony Biosciences LLC | $47.61 | 2021-2024 | Wakix |
| Regeneron Healthcare Solutions, INC. | $44.94 | 2019-2025 | Dupixent |
| Avanos Medical | $40.45 | 2021 | |
| Vapotherm INC | $34.65 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $34.36 | 2021-2023 | |
| United Therapeutics Corporation | $32.73 | 2024-2025 | Tyvaso, Tyvaso |
| Jazz Pharmaceuticals INC. | $30.65 | 2019-2022 | |
| Csl Behring | $24.23 | 2020 | |
| Abiomed | $20.43 | 2025 | |
| Baxter Healthcare | $18.49 | 2023 | Hillrom - Volara System |
| Insmed, INC. | $17.79 | 2025 | Arikayce |
| Pfizer INC. | $16.70 | 2022 | |
| Veran Medical Technologies, INC. | $14.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Violet Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.